• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

RFK re­moves all ACIP mem­bers, names new ones; Na­tion­al Re­silience to close six sites; Deals and fi­nanc­ing re­cap of ...

Yesterday
Weekly

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

Yesterday
Deals
Health Tech

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

Yesterday
Pharma
FDA+

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

Yesterday
Pharma
FDA+

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Yesterday
People
FDA+

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

2 days ago
Pharma
In Focus

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

2 days ago
News Briefing

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

2 days ago
Peer Review

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

2 days ago
R&D
China

Mod­er­na wins ex­pand­ed la­bel for RSV shot, al­low­ing use in at-risk, younger adults

2 days ago
Pharma
FDA+

Min­neso­ta gener­ic drug pric­ing law is like­ly un­con­sti­tu­tion­al, ap­peals court rules

2 days ago
Pharma
Law

No­vo Nordisk plans Phase 3 tri­als of oral, in­jectable amy­cretin for ear­ly 2026

2 days ago
R&D
Pharma

Kennedy's vac­cine doubts hinge on 'in­ert' place­bos, but ex­perts say he mis­un­der­stands the sci­ence

2 days ago
Pharma
FDA+

Cure­Vac CEO on BioN­Tech deal: Come to­geth­er 'rather than fight­ing each oth­er in court'

2 days ago
Deals

An­oth­er care nav­i­ga­tion deal

2 days ago
Health Tech

In sur­prise, FDA ap­proves Uro­Gen's chemo-turned-gel drug af­ter neg­a­tive ad­comm vote

2 days ago
Pharma
FDA+

Ex­clu­sive: Kennedy picks for vac­cine ad­vi­so­ry board were paid ex­perts against Mer­ck in civ­il cas­es

2 days ago
R&D
Pharma

In­smed aims to raise $750M in one of the largest stock of­fer­ings this year

2 days ago
Financing
R&D

Ku­ra, Ky­owa say Phase 1 up­date sup­ports menin in­hibitor com­bos 

2 days ago
R&D

ADC Ther­a­peu­tics re­veals lay­offs, $100M PIPE; Third Har­mon­ic seeks buy­er for as­set

3 days ago
News Briefing

Capri­cor gets Form 483 from FDA; WuXi Bi­o­log­ic­s' new Chi­na fac­to­ry 

3 days ago
Manufacturing

Ex­clu­sive: Com­mons Clin­ic rais­es $26M Se­ries B to of­fer pre­ven­tive test­ing

3 days ago
Financing
Startups

BioN­Tech to ac­quire Cure­Vac in all-stock deal val­ued at $1.25B

3 days ago
Deals

Schrödinger says ear­ly MALT1 da­ta could lay 'great foun­da­tion' for com­bos

3 days ago
R&D
1234 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times